305 related articles for article (PubMed ID: 15806320)
41. Two novel mutations in the alpha-galactosidase A gene in Chinese patients with Fabry disease.
Yang CC; Lai LW; Whitehair O; Hwu WL; Chiang SC; Lien YH
Clin Genet; 2003 Mar; 63(3):205-9. PubMed ID: 12694230
[TBL] [Abstract][Full Text] [Related]
42. An intronic haplotype in α galactosidase A is associated with reduced mRNA expression in males with cryptogenic stroke.
Zeevi DA; Hakam-Spector E; Herskovitz Y; Beeri R; Elstein D; Altarescu G
Gene; 2014 Oct; 549(2):275-9. PubMed ID: 25101867
[TBL] [Abstract][Full Text] [Related]
43. Structure-function relationships in alpha-galactosidase A.
Garman SC
Acta Paediatr; 2007 Apr; 96(455):6-16. PubMed ID: 17391432
[TBL] [Abstract][Full Text] [Related]
44. X-chromosomal inactivation patterns in women with Fabry disease.
Wagenhäuser L; Rickert V; Sommer C; Wanner C; Nordbeck P; Rost S; Üçeyler N
Mol Genet Genomic Med; 2022 Sep; 10(9):e2029. PubMed ID: 35971858
[TBL] [Abstract][Full Text] [Related]
45. Absence of α-galactosidase cross-correction in Fabry heterozygote cultured skin fibroblasts.
Fuller M; Mellett N; Hein LK; Brooks DA; Meikle PJ
Mol Genet Metab; 2015 Feb; 114(2):268-73. PubMed ID: 25468650
[TBL] [Abstract][Full Text] [Related]
46. Fabry disease: twenty novel alpha-galactosidase A mutations and genotype-phenotype correlations in classical and variant phenotypes.
Germain DP; Shabbeer J; Cotigny S; Desnick RJ
Mol Med; 2002 Jun; 8(6):306-12. PubMed ID: 12428061
[TBL] [Abstract][Full Text] [Related]
47. Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene.
Bernstein HS; Bishop DF; Astrin KH; Kornreich R; Eng CM; Sakuraba H; Desnick RJ
J Clin Invest; 1989 Apr; 83(4):1390-9. PubMed ID: 2539398
[TBL] [Abstract][Full Text] [Related]
48. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study--screening genetic conditions in Portuguese young stroke patients.
Baptista MV; Ferreira S; Pinho-E-Melo T; Carvalho M; Cruz VT; Carmona C; Silva FA; Tuna A; Rodrigues M; Ferreira C; Pinto AA; Leitão A; Gabriel JP; Calado S; Oliveira JP; Ferro JM;
Stroke; 2010 Mar; 41(3):431-6. PubMed ID: 20110537
[TBL] [Abstract][Full Text] [Related]
49. [Pedigree investigation of clinicopathologic features and alpha-galactosidase A gene mutation in a family with Fabry disease].
Liu XX; Yu CW; Yang Y; Hu ZX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Nov; 43(6):948-51. PubMed ID: 23387234
[TBL] [Abstract][Full Text] [Related]
50. [alpha-Galactosidase gene mutation and its expression product in Fabry disease (alpha-galactosidase deficiency)].
Okumiya T; Takata T; Sasaki M; Sakuraba H
Rinsho Byori; 1997 Feb; 45(2):127-35. PubMed ID: 9120996
[TBL] [Abstract][Full Text] [Related]
51. A sensitive mutation screening strategy for Fabry disease: detection of nine mutations in the alpha-galactosidase A gene.
Blanch LC; Meaney C; Morris CP
Hum Mutat; 1996; 8(1):38-43. PubMed ID: 8807334
[TBL] [Abstract][Full Text] [Related]
52. Oligosymptomatic cornea verticillata in a heterozygote for Fabry disease: a novel mutation in the alpha-galactosidase gene.
Kono JO; Podskarbi T; Shin Y; Lanzl I
Cornea; 2003 Mar; 22(2):175-7. PubMed ID: 12605057
[TBL] [Abstract][Full Text] [Related]
53. [Contribution of genotyping in Fabry's disease].
Froissart R; Piraud M; Maire I
Rev Med Interne; 2010 Dec; 31 Suppl 2():S275-8. PubMed ID: 21211679
[TBL] [Abstract][Full Text] [Related]
54. Fabry disease in patients with end-stage renal failure: the potential benefits of screening.
Bekri S; Enica A; Ghafari T; Plaza G; Champenois I; Choukroun G; Unwin R; Jaeger P
Nephron Clin Pract; 2005; 101(1):c33-8. PubMed ID: 15886492
[TBL] [Abstract][Full Text] [Related]
55. Correlation between interleukin-6 promoter and C-reactive protein (CRP) polymorphisms and CRP levels with the Mainz Severity Score Index for Fabry disease.
Altarescu G; Chicco G; Whybra C; Delgado-Sanchez S; Sharon N; Beck M; Elstein D
J Inherit Metab Dis; 2008 Feb; 31(1):117-23. PubMed ID: 18172744
[TBL] [Abstract][Full Text] [Related]
56. Pitfalls of X-chromosome inactivation testing in females with Fabry disease.
Řeboun M; Sikora J; Magner M; Wiederlechnerová H; Černá A; Poupětová H; Štorkánova G; Mušálková D; Dostálová G; Goláň L; Linhart A; Dvořáková L
Am J Med Genet A; 2022 Jul; 188(7):1979-1989. PubMed ID: 35338595
[TBL] [Abstract][Full Text] [Related]
57. [Genetic and clinical study of three Chinese pedigrees with Fabry disease].
Tian ML; Yan YL; Xiong JC; Liu XX; Yang Y; Hu ZX
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):185-8. PubMed ID: 23568732
[TBL] [Abstract][Full Text] [Related]
58. A family with various symptomatology suggestive of Anderson-Fabry disease and a genetic polymorphism of alpha galactosidase A gene.
Tuttolomondo A; Duro G; Pecoraro R; Simonetta I; Miceli S; Colomba P; Zizzo C; Di Chiara T; Scaglione R; Della Corte V; Corpora F; Pinto A
Clin Biochem; 2015 Jan; 48(1-2):55-62. PubMed ID: 25281798
[TBL] [Abstract][Full Text] [Related]
59. Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.
Duro G; Musumeci MB; Colomba P; Zizzo C; Albeggiani G; Mastromarino V; Volpe M; Autore C
Gene; 2014 Feb; 535(2):365-9. PubMed ID: 24140492
[TBL] [Abstract][Full Text] [Related]
60. A novel GLA mutation in a Fabry family with glucose-6-phosphate dehydrogenase deficiency.
Pisani A; Visciano B; Russo R; Mozzillo GR; Porto C; De Maggio I; Russo R; Pontarelli G; Villani GR; Cianciaruso B; Di Natale P
J Nephrol; 2012; 25(4):582-5. PubMed ID: 22307442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
